A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
The US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.